-
Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
-
RBC Capital Adds Speculative Risk Qualifier to INSYS Therapeutics (INSY) amid DOJ Uncertainty; PT Lowered to $16
-
Insys Therapeutics (INSY): DOJ Settlement Needed - RBC
-
Insys Therapeutics (INSY): Pipeline Progressing - RBC
-
Insys Therapeutics (INSY): Cutting PT On Unexpected CEO Succession - RBC
-
Insys Therapeutics (INSY): Syndros Approval Should Contribute $220M - RBC
-
RBC Cuts Insys Therapeutics (INSY) PT By 27%
-
Notable 52-Week Highs and Lows 4/11: (KGC) (SAND) (AU) High; (UA) (INSY) (PAHC) Low
-
Pre-Open Stock Movers 04/11: (VKTX) (HTS) (CHK) Higher; (OMEX) (MDXG) (INSY) (HTZ) Lower (more...)
-
Insys Therapeutics, Inc. to Present at RBC Capital Markets 2016 Global Healthcare Conference
-
RBC Capital Remains Bullish on Insys Therapeutics (INSY) as Shares Respond to Enthusiasm and Growth
-
Endo (ENDP) Has No Linden Care Exposure - RBC Capital
-
INSYS (INSY) 'Overreacting' to Linden Care News - RBC Capital
-
RBC Capital Starts INSYS Therapeutics (INSY) at Outperform